In Vitro Testing of Lung Carcinogenicity for an In Silico-Identified Cluster of Mycotoxins

被引:1
作者
Habauzit, Denis [1 ]
Alvarino, Rebeca [2 ,3 ]
Perez-Fuentes, Nadia [2 ,3 ]
Huet, Sylvie [1 ]
Alfonso, Amparo [2 ,3 ]
Hogeveen, Kevin [1 ]
Botana, Luis M. [2 ,3 ]
Fessard, Valerie [1 ]
机构
[1] French Agcy Food Environm & Occupat Hlth & Safety, Fougeres, France
[2] Univ Santiago De Compostela, Fac Vet, Dept Farmacol, Lugo 27002, Spain
[3] Grp Invest Biodiscovery, IDIS, Lugo 27002, Spain
基金
欧盟地平线“2020”;
关键词
Hazard; In vitro testing; Viability; Apoptosis; Cell cycle; Inflammation; NF-KAPPA-B; APOPTOSIS; INVOLVEMENT; CELLS; METABOLITES; INHIBITOR; BEAUVERICIN; ACTIVATION; AFLATOXINS; RESISTANCE;
D O I
10.1007/s12403-023-00601-9
中图分类号
TV21 [水资源调查与水利规划];
学科分类号
081501 ;
摘要
Occurrence of emerging mycotoxins in food and feed is reported worldwide, but studies on their toxic effects are still limited. Our previous study based on in silico approaches has evidenced an association between some cyclic peptidic mycotoxins and non-small cell lung cancer. In this work, an in vitro toxicological investigation of these mycotoxins (enniatin A, enniatin B, beauvericin, apicidin and destruxin B) was performed. Several pathways involved in lung cancer pathology, as revealed by the KEGG pathway map, were tested on A549 and NCI-H226 human lung cells. Effects on viability, apoptosis, cell cycle, DNA damage, reactive oxygen species, and IL-8 secretion were determined after 24-h mycotoxin treatment at concentrations between 0.01 and 100 & mu;M. Enniatin A, beauvericin and apicidin presented a similar response for all endpoints. Moreover, they were the most toxic compounds, with IC50 around 2.2 and 13.1 & mu;M, and apoptosis induction in both cell lines. Enniatin B did not induce a complete decrease in cell viability and did not provoke apoptosis. Destruxin B increased caspase 3 activity and altered cell cycle at concentrations above 6.25 & mu;M in A549 cells, suggesting apoptosis activation, although it did not reduce cell viability in either cell line. Finally, enniatins A and B, apicidin, beauvericin and destruxin B increased the release of the pro-inflammatory IL-8. The in vitro results of this work confirmed the prediction using in silico approaches as some hallmarks of cancer can be observed after treatment of lung cells with this mycotoxin cluster. The toxic effects observed in human lung cells confirmed that the presence of these emerging mycotoxins in agricultural products, food and feed might be hazardous for human health and that a link with lung cancer was further outlined for three of them.
引用
收藏
页码:943 / 958
页数:16
相关论文
共 50 条
  • [41] Elsholtzia bodinieri Vaniot Ameliorated Acute Lung Injury by NQO1, BCL2 and PTGS2 In Silico and In Vitro Analyses
    Sun, Jin
    Jiang, Xiaoqian
    Chen, Yuxu
    Guo, Shancheng
    Zhao, Zhiye
    Cao, Jianxin
    Liu, Yaping
    Cheng, Guiguang
    Li, Ye
    Tian, Lei
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)
  • [42] Development, testing, parameterisation, and calibration of a human PBK model for the plasticiser, di (2-ethylhexyl) adipate (DEHA) using in silico, in vitro and human biomonitoring data
    McNally, Kevin
    Sams, Craig
    Loizou, George
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [43] In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker Genes
    Alamery, Salman
    Alajmi, Anfal
    Wani, Tanveer A.
    Zargar, Seema
    MEDICINA-LITHUANIA, 2023, 59 (11):
  • [44] In vivo, in vitro, and in silico approaches in the detailed study of di-butyl phthalate (DBP), a plasticizer-induced lung fibrosis via Nrf-2/Keap-1/HO-1 pathway and its regulation
    Singh, Payal
    Kumari, Sneha
    Chakravortty, Harshika
    Pandey, Ajai
    Dash, D.
    Singh, Rashmi
    BIOORGANIC CHEMISTRY, 2025, 154
  • [45] Filling the Concept with Data: Integrating Data from Different In Vitro and In Silico Assays on Skin Sensitizers to Explore the Battery Approach for Animal-Free Skin Sensitization Testing
    Natsch, Andreas
    Emter, Roger
    Ellis, Graham
    TOXICOLOGICAL SCIENCES, 2009, 107 (01) : 106 - 121
  • [46] Development, Testing, Parameterisation and Calibration of a Human PBPK Model for the Plasticiser, Di-(2-propylheptyl) Phthalate (DPHP) Using in Silico, in vitro and Human Biomonitoring Data
    McNally, Kevin
    Sams, Craig
    Hogg, Alex
    Lumen, Annie
    Loizou, George
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [47] PI3K/mTOR Inhibitor VS-5584 Alters Expression of WNT Signaling Genes and Induces Apoptosis in Lung Adenocarcinoma Cells: In Vitro and In Silico Insight
    Ozel, Buket
    Kipcak, Sezgi
    Caglar, Hasan Onur
    Kayabasi, Cagla
    Bagca, Bakiye Goker
    Gunduz, Cumhur
    Gunel, Nur Selvi
    Avci, Cigir Biray
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2024, : 2313 - 2322
  • [48] In silico identification and in vitro validation of nogalamycin N-oxide (NSC116555) as a potent anticancer compound against non-small-cell lung cancer cells
    Obounchoey, Phongphat
    Tabtimmai, Lueacha
    Suphakun, Praphasri
    Thongkhao, Kannika
    Eurtivong, Chatchakorn
    Gleeson, Matthew Paul
    Choowongkomon, Kiattawee
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (03) : 3353 - 3361
  • [49] Effects of Methadone on the Toll-like Receptor 4 Expression in Human Non-Small Cell Lung Carcinoma A549 Cell Line Using In-silico and In vitro Techniques
    Vaseghi, Golnaz
    Rashidi, Nastaran
    Zare, Nasrin
    Ghasemi, Fahimeh
    Pourhadi, Marjan
    Rafiee, Laleh
    Javanmard, Shaghayegh Haghjooy
    ADVANCED BIOMEDICAL RESEARCH, 2022, 11 (01):
  • [50] Enhancing breast cancer treatment: Comprehensive study of gefitinib-loaded poloxamer 407/TPGS mixed micelles through design, development, in-silico modelling, In-Vitro testing, and Ex-Vivo characterization
    Chary, Padakanti Sandeep
    Bansode, Ankush
    Rajana, Naveen
    Bhavana, Valamla
    Singothu, Siva
    Sharma, Anamika
    Guru, Santosh Kumar
    Bhandari, Vasundhra
    Mehra, Neelesh Kumar
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 657